Embryonal Tumors of Infancy & Childhood: South Egypt Cancer Institute Experience
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Neoplasms, Embryonal
- Sponsor
- Assiut University
- Enrollment
- 420
- Locations
- 1
- Primary Endpoint
- Overall survival (OS)
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The aim of this study is to investigate demographic & disease characteristics of pediatric cancer patients diagnosed with one of embryonal tumors to identify the prevalence, the spectrum of these disease entities & treatment outcomes in these patients.
Detailed Description
Background: Embryonal tumors arise from cells that are normally present in the developing embryo and originate in developing tissues and organ systems. These tumors occur almost exclusively in children, and are usually diagnosed in children before age 5 years. The group is heterogeneous and includes relatively common pediatric tumors as well as rare tumors. Three common types of embryonal tumors in children are neuroblastoma, Wilms tumor (WT), and retinoblastoma. Other embryonal tumors, include medulloblastoma and rhabdomyosarcoma. Patients \& Methods: From January 2001 to December 2015, retrieval \& analysis of the medical records of pediatric patients with embryonal tumors will be made at the pediatric oncology department, South Egypt Cancer Institute which represents the largest referral center in Upper Egypt. These data will be categorized according to demographic characteristics, clinico-pathologic features, treatment modalities received, and outcomes of treatments in these patients.
Investigators
Ahmed Mohammed Morsy, MD
Lecturer, Pediatric Oncology Department
Assiut University
Eligibility Criteria
Inclusion Criteria
- •Patients whose age less than or equal to 18 years.
- •Patients diagnosed with any of embryonal neoplasms.
Exclusion Criteria
- •Patients whose age more than 18 years.
Outcomes
Primary Outcomes
Overall survival (OS)
Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years
Time from the date of initiation of treatment until death from any cause
Event Free Survival (EFS)
Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years
Time from the date of initiation of treatment until disease progression, or death for any reason